Interventional Oncology

Interventional Oncology Market Outlook

The global Interventional Oncology market is expected to reach approximately USD 6.4 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of around 11.5% from 2025 to 2035. This market growth is primarily driven by the increasing prevalence of cancer worldwide, with estimates suggesting that nearly 10 million people succumbed to cancer in 2020 alone, according to the World Health Organization. Moreover, advancements in interventional techniques, innovations in medical equipment, and the growth of outpatient care services are contributing significantly to the market dynamics. Furthermore, the rising focus on personalized medicine and targeted therapies is fostering the demand for minimally invasive procedures, which are known to cause less discomfort and promote quicker recovery. Additionally, the increasing investment in research and development by pharmaceutical and biotech companies is expected to generate more advanced therapeutic options, thereby further stimulating market growth.

Growth Factor of the Market

Several factors are propelling the growth of the Interventional Oncology market, with a prime focus on rising cancer incidences globally. As populations age, the prevalence of cancer is expected to rise, necessitating innovative treatment options. Moreover, the advent of advanced imaging techniques and minimally invasive procedures has drastically improved the precision and effectiveness of interventional oncology treatments. Additionally, there is a growing trend toward outpatient procedures, which has led to increased patient throughput and reduced healthcare costs. As healthcare providers look to optimize treatment outcomes while minimizing complications, interventional oncology techniques such as ablation and embolization have gained traction. Furthermore, the supportive regulatory environment and increasing funding for cancer research and treatment innovations are additional vital factors that are expected to maintain a positive trajectory for the market.

Key Highlights of the Market

• The Interventional Oncology market is projected to experience a CAGR of 11.5% from 2025 to 2035.
• Minimally invasive procedures are becoming the preferred choice for cancer treatment due to lesser complications.
• Technological advancements in imaging and medical devices are significantly enhancing treatment efficacy.
• Outpatient care services are on the rise, thereby increasing patient accessibility to interventional oncology treatments.
• Strategic collaborations and partnerships among businesses are driving innovation in treatment methodologies.

By Procedure Type

Tumor Ablation:

Tumor ablation is a minimally invasive treatment that destroys cancerous tissue using various energy sources, such as heat or cold. It has gained immense popularity due to its effectiveness in treating localized tumors without the need for extensive surgery. Techniques such as radiofrequency ablation (RFA) and microwave ablation are common methods used, which allow for precise targeting and minimal damage to surrounding healthy tissue. The growing acceptance of tumor ablation procedures is driven by favorable outcomes, shorter recovery times, and reduced hospital stays. Furthermore, with an increasing number of clinical studies validating the effectiveness of tumor ablation, this procedure type is likely to dominate the Interventional Oncology market in the coming years.

Transarterial Chemoembolization:

Transarterial Chemoembolization (TACE) is a targeted approach that combines chemotherapy and embolization to treat liver cancer primarily. By delivering chemotherapy directly to the tumor while simultaneously blocking its blood supply, TACE enhances the efficacy of the treatment while minimizing systemic side effects. This procedure is particularly beneficial for patients with unresectable tumors, as it helps shrink tumors and control cancer progression. The increasing incidence of liver cancer, especially in regions with high rates of hepatitis infections, has significantly driven the demand for TACE. Furthermore, advancements in catheter technologies and imaging techniques are improving TACE's delivery and success rates, making it a crucial segment in the Interventional Oncology market.

Radioembolization:

Radioembolization, also known as selective internal radiation therapy (SIRT), is an innovative treatment combining embolization with radiation therapy to target tumors, primarily in the liver. This procedure involves injecting radioactive microspheres into the blood vessels feeding the tumor, allowing localized radiation treatment that spares surrounding healthy tissues. As a result, radioembolization has emerged as a vital therapeutic option for patients with liver tumors who are not candidates for surgery. The growing awareness regarding its benefits, coupled with the increasing number of clinical trials supporting its efficacy, is expected to fuel the growth of this procedure type in the Interventional Oncology market.

Percutaneous Biopsy:

Percutaneous biopsy plays a critical role in the diagnosis of cancer by allowing healthcare providers to collect tissue samples from tumors through the skin, guiding them with imaging technologies. This procedure is less invasive than traditional surgical biopsies and offers faster recovery times, thereby increasing its adoption among patients and healthcare facilities. The increasing emphasis on accurate cancer diagnosis and the growing number of cancer cases are driving the demand for percutaneous biopsies. Moreover, advancements in needle technology and imaging modalities have significantly enhanced the accuracy and safety of this biopsy type, further solidifying its position in the Interventional Oncology market.

Targeted Drug Delivery:

Targeted drug delivery systems have revolutionized cancer treatment by allowing for the direct delivery of therapeutic agents to cancer cells, reducing systemic exposure and side effects. This procedure type is particularly effective in treating tumors that are less responsive to conventional treatments. The integration of advanced drug delivery systems and imaging techniques ensures precise targeting and optimal drug release, further improving treatment outcomes. Additionally, the increasing focus on personalized medicine is propelling the growth of targeted drug delivery methods in the Interventional Oncology market, as it aligns well with the tailored approaches to cancer treatment.

By Cancer Type

Liver Cancer:

Liver cancer is one of the leading causes of cancer deaths globally and significantly influences the Interventional Oncology market. With rising rates of hepatitis infections and cirrhosis, the demand for effective treatment options for liver cancer has surged. Interventional oncology procedures, such as tumor ablation and transarterial chemoembolization, have become critical components of the treatment regimen for liver cancer, as they allow for localized treatment with minimal side effects. Furthermore, ongoing research to improve the efficacy of existing therapies is expected to enhance patient outcomes, thereby driving the growth of the liver cancer segment in the market.

Lung Cancer:

Lung cancer remains a significant public health challenge and is the leading cause of cancer-related deaths worldwide. The increasing prevalence of smoking, exposure to environmental pollutants, and genetic factors contribute to a rising incidence of lung cancer. Interventional oncology techniques, such as radiofrequency ablation and percutaneous biopsy, are increasingly being employed to treat lung tumors effectively. The growing focus on early diagnosis and minimally invasive therapies is expected to spur the demand for interventional procedures in lung cancer management, making it a vital segment of the market.

Breast Cancer:

Breast cancer is one of the most common cancers affecting women globally, leading to a growing need for innovative treatment options. Interventional oncology plays a pivotal role in managing breast cancer through techniques such as targeted drug delivery and percutaneous biopsy. These procedures not only assist in accurate diagnosis but also facilitate localized treatment, thus improving patient outcomes. Additionally, the rising awareness and advocacy regarding breast cancer screening and treatment options further contribute to the growth of the breast cancer segment within the Interventional Oncology market.

Prostate Cancer:

Prostate cancer is the most common cancer among men, which has driven the demand for effective treatment options in recent years. Interventional oncology techniques, including cryoablation and targeted drug delivery, offer unique advantages in managing prostate cancer, enabling precise targeting and minimizing collateral damage to surrounding tissues. The growing preference for minimally invasive procedures among patients and healthcare providers is expected to bolster the prostate cancer segment, fostering the overall growth of the Interventional Oncology market.

Colorectal Cancer:

Colorectal cancer is a leading cause of cancer-related mortality, necessitating innovative treatment strategies. Interventional oncology approaches, such as tumor ablation and transarterial chemoembolization, are increasingly being utilized to manage colorectal cancer effectively. These procedures allow for localized treatment, which is crucial for patients with metastatic disease. The rising demand for minimally invasive therapies and the growing awareness surrounding colorectal cancer screening are key factors expected to stimulate the growth of this segment in the Interventional Oncology market.

By User

Hospitals:

Hospitals represent the largest end-user segment for interventional oncology procedures due to their comprehensive oncology departments and access to advanced technologies. As the primary healthcare facilities providing cancer treatment, hospitals are increasingly adopting interventional techniques to offer patients minimally invasive options. The trend toward outpatient services is also gaining traction, with many hospitals implementing day surgery programs to enhance patient throughput and improve recovery times. The increasing investment in healthcare infrastructure and technological advancements in hospitals further facilitate the growth of this segment in the Interventional Oncology market.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming increasingly popular for interventional oncology procedures due to their ability to provide same-day discharge and lower operational costs. These centers focus on outpatient surgeries, allowing patients to undergo treatments without the need for extensive hospital stays. The growing acceptance of ASCs among patients and healthcare providers, coupled with the rising demand for minimally invasive procedures, is expected to drive the growth of this segment in the Interventional Oncology market. Additionally, favorable reimbursement policies for outpatient services are further incentivizing the increased adoption of ASCs in cancer treatment.

Cancer Research Institutes:

Cancer research institutes are crucial players in the interventional oncology market as they focus on developing innovative treatment strategies and conducting clinical trials. These institutes play a pivotal role in advancing the understanding of cancer biology and improving therapeutic approaches. By facilitating research and development activities, cancer research institutes contribute to the emergence of new interventional oncology techniques, enhancing the overall quality of care for cancer patients. As the focus on personalized medicine and targeted therapies continues to grow, the demand for collaboration between these institutes and healthcare providers is expected to rise, stimulating growth in this segment.

Specialty Clinics:

Specialty clinics are increasingly providing targeted interventional oncology services, focusing on specific types of cancer or treatments. These clinics often employ specialized personnel and advanced technologies to deliver high-quality care tailored to individual patient needs. The growing trend of patient-centered care and the rising awareness of available treatment options are driving the demand for specialty clinics in the Interventional Oncology market. Furthermore, these clinics often facilitate faster access to care and shorter waiting times, making them an attractive option for patients seeking oncology treatments.

By Modality

Embolization:

Embolization is a minimally invasive procedure used to obstruct blood flow to a tumor, effectively starving it of the nutrients required for growth. This technique has gained substantial traction in interventional oncology, particularly for liver tumors, where transarterial chemoembolization (TACE) is commonly employed. The ability to deliver chemotherapy directly to the tumor while applying embolic agents offers a dual therapeutic approach. The growing body of clinical evidence supporting the efficacy of embolization techniques is expected to drive their adoption and growth within the Interventional Oncology market.

Radiofrequency Ablation:

Radiofrequency ablation (RFA) is a well-established technique that utilizes heat generated from radio waves to destroy tumor cells. This modality has become increasingly popular for treating small tumors in various organs, including the liver, lungs, and kidneys. The advantages of RFA, such as minimal invasiveness, shorter recovery times, and outpatient procedures, make it a compelling option for patients. As healthcare providers continue to adopt innovative technologies and expand their capabilities in performing RFA, the demand for this modality in the Interventional Oncology market is expected to rise significantly.

Cryoablation:

Cryoablation is an innovative technique that employs extreme cold to induce cell death in tumors. This modality is particularly effective for certain types of tumors, including those in the kidney and lung. Cryoablation offers several advantages, including minimal damage to surrounding tissues and the potential for real-time monitoring of tumor response. As more clinical research demonstrates the effectiveness of cryoablation in various oncological applications, its adoption in the Interventional Oncology market is anticipated to grow steadily. Additionally, the advancements in cryoablation technology and techniques will enhance its overall efficacy and patient outcomes.

Microwave Ablation:

Microwave ablation is a promising technique that utilizes microwave energy to generate heat, effectively destroying tumor cells. This modality is especially beneficial for larger tumors that may not be amenable to other ablative techniques. Microwave ablation offers several benefits, including shorter procedure times and enhanced precision in targeting tumors. The growing acceptance of microwave ablation among healthcare providers, coupled with the rising demand for minimally invasive procedures, is expected to fuel its growth in the Interventional Oncology market. Furthermore, ongoing advancements in microwave technologies are likely to enhance treatment outcomes and expand its applications.

High-Intensity Focused Ultrasound:

High-Intensity Focused Ultrasound (HIFU) is an innovative non-invasive treatment method that employs focused ultrasound waves to generate localized heat, effectively destroying tumor cells. HIFU is gaining traction in the Interventional Oncology market due to its ability to treat tumors in various locations without damaging surrounding healthy tissues. The technology is particularly beneficial for patients who are unable to undergo traditional surgery due to health concerns. As the body of clinical evidence supporting HIFU grows, alongside advancements in ultrasound technologies, its adoption is expected to rise, positioning it as a significant modality in interventional oncology.

By Region

The Interventional Oncology market is primarily dominated by regions such as North America, Europe, and Asia Pacific, which collectively account for a significant share of the global market. North America is the largest market, driven by advanced healthcare infrastructure, increasing adoption of minimally invasive procedures, and high prevalence rates of cancer. The region is projected to maintain a CAGR of around 10% over the forecast period, fueled by continuous technological advancements and a robust pipeline of innovative interventional oncology products. The presence of major market players and strong governmental support for cancer research also contribute to the growth of the market in North America.

Europe follows closely, with a growing incidence of cancer and increasing patient awareness regarding interventional oncology techniques. The European market is characterized by a strong focus on research and innovation, with numerous clinical trials and collaborations aimed at enhancing treatment methods. The Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by rising healthcare expenditure, increasing investments in healthcare infrastructure, and growing awareness of cancer treatment options. With the rising prevalence of cancer in emerging economies like India and China, the demand for interventional oncology procedures is expected to surge significantly in this region.

Opportunities

The Interventional Oncology market presents numerous opportunities for growth, especially considering the increasing prevalence of cancer worldwide. With an ever-growing patient population seeking innovative treatment options, companies are encouraged to invest in the development of advanced technologies and procedures. The shift towards personalized medicine also opens up avenues for more tailored interventional oncology treatments, as healthcare providers seek to provide customized care based on individual patient needs. Collaborations between technology developers, healthcare providers, and research institutions can lead to the rapid advancement of new techniques that enhance treatment efficacy and safety. Additionally, the increasing focus on outpatient care presents substantial opportunities for market players to expand their offerings and enhance patient accessibility to interventional oncology procedures.

Furthermore, expanding into emerging markets can be a lucrative opportunity for companies in the Interventional Oncology sector. With rising healthcare expenditures and increased awareness of cancer treatment options in regions such as Asia Pacific and Latin America, there is significant potential for growth. Establishing partnerships with local healthcare providers and investing in regional healthcare infrastructure can help facilitate the adoption of interventional oncology techniques among patients. Additionally, ongoing advancements in medical imaging and technology are likely to improve the accuracy and efficiency of interventional procedures, further driving demand and creating new opportunities for market players.

Threats

Despite the promising growth prospects of the Interventional Oncology market, several threats could hinder its progress. One critical threat is the increasing competition among market players, which may lead to price wars and reduced profit margins. As more companies enter the interventional oncology space, the market may become saturated, potentially limiting growth opportunities for existing players. Additionally, the high costs associated with developing advanced interventional oncology technologies and devices may pose financial challenges, particularly for smaller companies and startups. Regulatory hurdles and the need for extensive clinical trials can further delay the introduction of new products into the market, impacting overall growth.

Moreover, patient reluctance towards undergoing interventional procedures due to fear of complications or adverse effects could impact market growth. Public perceptions of safety associated with minimally invasive procedures can significantly influence patient choice, leading to delays in treatment or preference for traditional options. Furthermore, the ongoing global economic uncertainties may result in reduced healthcare budgets, limiting investments in advanced interventional oncology technologies and hindering market expansion.

Competitor Outlook

• Medtronic
• Boston Scientific Corporation
• Johnson & Johnson
• Varian Medical Systems
• Siemens Healthineers
• Fujifilm Holdings Corporation
• AngioDynamics
• Cook Medical
• Hologic, Inc.
• Abbott Laboratories
• Neuwave Medical, Inc.
• Radiaction Medical
• Argon Medical Devices
• InSightec
• Insight Therapeutics

The competitive landscape of the Interventional Oncology market is characterized by the presence of several major players, each striving to innovate and capture market share. Companies are heavily investing in research and development to create cutting-edge technologies and advanced treatment modalities that can improve patient outcomes. Strategic collaborations, mergers and acquisitions, and partnerships are common strategies employed by market participants to enhance their product offerings and expand their geographical reach. Furthermore, leading companies are actively engaging in clinical trials to validate the safety and efficacy of their products, which in turn bolsters their competitive position in the market.

Medtronic, one of the foremost players in the Interventional Oncology market, offers an extensive portfolio of products, including advanced tumor ablation systems and embolization devices. The company's strong presence in the market is supported by its commitment to innovation and ongoing clinical research, enabling it to stay ahead of the competition. Similarly, Boston Scientific Corporation has made significant strides in the interventional oncology space through its advanced technologies and effective treatment solutions, focusing on improving patient outcomes and enhancing procedural efficiency.

Another key player, Johnson & Johnson, leverages its extensive experience in the healthcare sector to provide comprehensive interventional oncology solutions. The company focuses on optimizing treatment methodologies while ensuring patient safety and satisfaction. Additionally, Varian Medical Systems has positioned itself as a leader in delivering targeted therapies for radiation oncology, contributing significantly to the growth of the Interventional Oncology market. The company's commitment to advancing cancer treatment through innovative technologies has made it a formidable force in the industry. As competition intensifies, these major players will continue to shape the future of the Interventional Oncology market, driven by their dedication to innovation and improving patient care.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 InSightec
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Cook Medical
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AngioDynamics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hologic, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Radiaction Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Insight Therapeutics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Argon Medical Devices
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Neuwave Medical, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Varian Medical Systems
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Fujifilm Holdings Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Interventional Oncology Market, By user
    • 6.1.1 Hospitals
    • 6.1.2 Ambulatory Surgical Centers
    • 6.1.3 Cancer Research Institutes
    • 6.1.4 Specialty Clinics
  • 6.2 Interventional Oncology Market, By Modality
    • 6.2.1 Embolization
    • 6.2.2 Radiofrequency Ablation
    • 6.2.3 Cryoablation
    • 6.2.4 Microwave Ablation
    • 6.2.5 High-Intensity Focused Ultrasound
  • 6.3 Interventional Oncology Market, By Cancer Type
    • 6.3.1 Liver Cancer
    • 6.3.2 Lung Cancer
    • 6.3.3 Breast Cancer
    • 6.3.4 Prostate Cancer
    • 6.3.5 Colorectal Cancer
  • 6.4 Interventional Oncology Market, By Procedure Type
    • 6.4.1 Tumor Ablation
    • 6.4.2 Transarterial Chemoembolization
    • 6.4.3 Radioembolization
    • 6.4.4 Percutaneous Biopsy
    • 6.4.5 Targeted Drug Delivery

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Interventional Oncology Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Interventional Oncology market is categorized based on

By Procedure Type

• Tumor Ablation
• Transarterial Chemoembolization
• Radioembolization
• Percutaneous Biopsy
• Targeted Drug Delivery

By Cancer Type

• Liver Cancer
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer

By user

• Hospitals
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Specialty Clinics

By Modality

• Embolization
• Radiofrequency Ablation
• Cryoablation
• Microwave Ablation
• High-Intensity Focused Ultrasound

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic
• Boston Scientific Corporation
• Johnson & Johnson
• Varian Medical Systems
• Siemens Healthineers
• Fujifilm Holdings Corporation
• AngioDynamics
• Cook Medical
• Hologic, Inc.
• Abbott Laboratories
• Neuwave Medical, Inc.
• Radiaction Medical
• Argon Medical Devices
• InSightec
• Insight Therapeutics